FHIR © HL7.org  |  Server Home  |  FHIR Server FHIR Server 3.7.22-SNAPSHOT  |  FHIR Version n/a  User: [n/a]

1331983003: Tezepelumab (substance)


Status: current, Not sufficiently defined by necessary conditions definition status (core metadata concept). Date: 01-Apr 2024. Module: SNOMED CT core

Descriptions:

Id Description Lang Type Status Case? Module
5347998010 Tezepelumab en Synonym (core metadata concept) Active Entire term case insensitive (core metadata concept) SNOMED CT core
5347999019 Tezepelumab (substance) en Fully specified name Active Entire term case insensitive (core metadata concept) SNOMED CT core


0 descendants.

Expanded Value Set


Outbound Relationships Type Target Active Characteristic Refinability Group Values
Tezepelumab Is a Monoclonal immunoglobulin G (substance) true Inferred relationship Some

Inbound Relationships Type Active Source Characteristic Refinability Group
Tezepelumab 110 mg/mL solution for injection The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). True Tezepelumab Inferred relationship Some 1
Tezepelumab 110 mg/mL solution for injection This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. True Tezepelumab Inferred relationship Some 1
Product containing only tezepelumab in parenteral dose form (medicinal product form) The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. True Tezepelumab Inferred relationship Some 1
Tezepelumab only product The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. True Tezepelumab Inferred relationship Some 1
Tezepelumab-containing product in parenteral dose form The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. True Tezepelumab Inferred relationship Some 1
Tezepelumab-containing product The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. True Tezepelumab Inferred relationship Some 1

Reference Sets

Description inactivation indicator reference set

Back to Start